Since activated protein C neutralizing the coagulation factors Va and VIIIa, protein C deficiency predisposes the affected for venous thrombosis.

Since activated protein C neutralizing the coagulation factors Va and VIIIa, protein C deficiency predisposes the affected for venous thrombosis.

(See also thrombotic diseases at a glance.) Since activated protein C neutralizes the coagulation factors Va and VIIIa, protein C deficiency predisposes those affected for venous thrombosis. Protein C, as well as coagulation factors VII, IX and X, prothrombin, and protein S, and Z, a vitamin K-dependent protein. Since activated protein C (APC) leads to neutralization of the factors Va and VIIIa, APC is a physiological anticoagulant in the plasma. A lack of protein C from genetic or acquired reasons, increases the risk of venous thrombosis. The heterozygous protein C deficiency has with about 75% of all subjects undergo a prevalence of 0.2-0.5%, a venous thrombosis (50% by age 50). The homozygous or double heterozygous form results in newborns to the development of purpura fulminans, d. H. severe disseminated intravascular coagulation (DIC). An acquired decline occurs in patients with liver disease or DICauf and during therapy with warfarin. The diagnosis is made by a functional antigen and plasma test. Therapy anticoagulation in patients with symptomatic thrombosis should first be conducted anticoagulation with heparin or low molecular weight heparin, followed by treatment with vitamin K antagonist warfarin (n. D. Übers .: Instead of warfarin is usually used in Germany warfarin). Warfarin is used as initial therapy, it is due to a reduction of vitamin K-dependent protein C levels occasionally thrombotic infarcts skin as a therapeutic drop of the other vitamin K-dependent coagulation factors occur more slowly. It is not known if the newer oral anticoagulants, either thrombin (dabigatran) or factor Xa (z. B. rivaroxaban, apixaban) inhibit can be used for this disorder instead of other anticoagulants. Purpura fulminans the newborn runs usually fatal without substitution therapy with protein C (normal plasma or purified concentrates), without anticoagulant therapy with heparin or low molecular weight heparin.

Health Life Media Team

Leave a Reply